### Accepted Manuscript

#### Research paper

Pulmonary absorption - estimation of effective pulmonary permeability and tissue retention of ten drugs using an *ex-vivo* rat model and computational analysis

Johanna Eriksson, Erik Sjögren, Helena Thörn, Katarina Rubin, Per Bäckman, Hans Lennernäs

PII: S0939-6411(17)30819-6

DOI: https://doi.org/10.1016/j.ejpb.2017.11.013

Reference: EJPB 12637

To appear in: European Journal of Pharmaceutics and Biophar-

maceutics

Received Date: 7 August 2017 Revised Date: 23 November 2017 Accepted Date: 26 November 2017



Please cite this article as: J. Eriksson, E. Sjögren, H. Thörn, K. Rubin, P. Bäckman, H. Lennernäs, Pulmonary absorption - estimation of effective pulmonary permeability and tissue retention of ten drugs using an *ex-vivo* rat model and computational analysis, *European Journal of Pharmaceutics and Biopharmaceutics* (2017), doi: https://doi.org/10.1016/j.ejpb.2017.11.013

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## ACCEPTED MANUSCRIPT

Title page:

Pulmonary absorption - estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex-vivo rat model and computational analysis

Johanna Eriksson<sup>1</sup>, Erik Sjögren<sup>1</sup>, Helena Thörn<sup>2</sup>, Katarina Rubin<sup>3</sup>, Per Bäckman<sup>2,4</sup>, Hans Lennernäs<sup>1</sup>

<sup>1</sup>Department of Pharmacy, Uppsala University, Uppsala, 75233, Sweden

<sup>2</sup>Pharmaceutical Technology & Development Inhalation, AstraZeneca, Pepparedsleden 1, Mölndal, 43183, Sweden

<sup>3</sup>Respiratory, Inflammation & Autoimmunity, Innovative Medicines and Early Development, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden

<sup>4</sup>Current address: Mylan Global Respiratory Group, Mylan Pharma UK Ltd., Kent CT13 9FF, United Kingdom

#### Corresponding Author:

Hans Lennernäs Ph.D., Professor Biopharmaceutical Research Group Department of Pharmacy Uppsala University Box 580 SE-751 23 Uppsala Sweden

Telephone:

+46 18 471 4317

+46 18 471 4223 Fax:

hans.lennernas@farmaci.uu.se E-mail:

#### Download English Version:

# https://daneshyari.com/en/article/8412119

Download Persian Version:

https://daneshyari.com/article/8412119

<u>Daneshyari.com</u>